Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep595 | Pituitary and Neuroendocrinology | ECE2020

Gallium-68 -DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas

M. Boertien Tessel , Booij Jan , Majoie Charles BLM , Drent ML , Pereira Alberto M , Biermasz Nienke , Simsek Suat , Groote Veldman Ronald , Stokkel Marcel PM , Bisschop Peter H , Fliers Eric

Background: Clinically non-functioning pituitary macroadenomas (NFMA) have been reported to express various somatostatin receptor (SSTR) subtypes, but results are inconsistent across different studies. This may be related to limited sensitivity and specificity of techniques used to date, i.e. immunohistochemistry in surgical specimens and 111In-DTPA-octreotide scintigraphy (Octreoscan) in vivo. The aim of this study was to assess SSTR expression in NFMA <em...

ea0070ep340 | Pituitary and Neuroendocrinology | ECE2020

The galant trial: a randomised placebo-controlled trial in patients with a gallium-68 dotatate pet positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size

Boertien Tessel M. , Drent M.L. , Booij Jan , Majoie Charles B.L.M. , Stokkel Marcel P.M. , Hoogmoed Jantien , Pereira Alberto M , Biermasz Nienke , Simsek Suat , Veldman Ronald Groote , Tanck Michael W.T. , Fliers Eric , Bisschop Peter H.

Rationale: At present, there is no approved medical treatment for patients with clinically non-functioning pituitary adenoma. A number of open-label studies suggest that treatment with somatostatin analogues may prevent tumour progression in selected patients. In vivo assessment of somatostatin receptor status using 68Ga-DOTATATE PET could help to select patients responsive to treatment.Trial objective: To investigate the effect of the somatosta...